A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

NCT07286006 · tracked via the Priya Life Science Czechia tracker

Sponsor

Immunovant Sciences GmbH

Phase

Phase 2

Started

2026-01-26

Last updated

2026-09-29

Condition(s) studied

Graves' Disease

Investigational drug(s) / intervention(s)

IMVT-1402 →

IMVT-1402: Dose 1 for up to 52 weeks

Study summary

This is a long-term extension study that will rollover participants completing feeder studies IMVT-1402-2502 (NCT06727604) or IMVT-1402-2503 (NCT07018323) to evaluate the efficacy and safety of IMVT-1402 in adult participants with GD. Eligible participants will be assigned to 1 of 3 study groups (Groups A, B and C) based on their GD status at the completion of their respective feeder study.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participants who completed Study IMVT-1402-2502 or Study IMVT-1402-2503. * Other, more specific inclusion criteria are defined in the protocol. Exclusion Criteria: * Have permanently discontinued IMP during the treatment period in the feeder study or have met study stopping criteria at any point up until the end of participation in the feeder study.

Primary outcome measure(s)

Percentage of Group A Participants who remain euthyroid, Off ATD, and Off IMVT-1402 — At Week 52

Trial sites (131)

Facility	City	Region
Site Number - 1561	Phoenix	Arizona
Site Number - 1519	Phoenix	Arizona
Site Number - 1530	Tucson	Arizona
Site Number - 1510	Concord	California
Site Number - 1587	Huntington Beach	California
Site Number - 1554	Los Angeles	California
Site Number - 1588	Orange	California
Site Number - 1559	San Francisco	California
Site Number - 1558	Santa Clarita	California
Site Number - 1552	Torrance	California
Site Number - 1533	Aurora	Colorado
Site Number -1514	Englewood	Colorado
Site Number - 1516	Newark	Delaware
Site Number - 1567	Washington D.C.	District of Columbia
Site Number - 1556	Clearwater	Florida
Site Number - 1522	Doral	Florida
Site Number - 1523	Hialeah	Florida
Site Number - 1581	Jacksonville	Florida
Site Number - 1582	Jacksonville	Florida
Site Number - 1505	Miami	Florida
Site Number - 1564	Miami	Florida
Site Number - 1591	Miami	Florida
Site Number - 1590	Ocoee	Florida
Site Number - 1508	Orlando	Florida
Site Number - 1507	Port Charlotte	Florida
Site Number - 1548	West Palm Beach	Florida
Site Number - 1566	Atlanta	Georgia
Site Number - 1526	Columbus	Georgia
Site Number - 1579	Macon	Georgia
Site Number - 1518	Stockbridge	Georgia
Site Number - 1562	Indianapolis	Indiana
Site Number - 1568	Kansas City	Kansas
Site Number - 1534	Topeka	Kansas
Site Number - 1571	Bowling Green	Kentucky
Site Number - 1580	Florence	Kentucky
Site Number - 1546	Louisville	Kentucky
Site Number - 1589	Metairie	Louisiana
Site Number - 1555	New Orleans	Louisiana
Site Number - 1565	Baltimore	Maryland
Site Number - 1557	Boston	Massachusetts

+ 91 more sites — see the full list on the official registry below.

More Immunovant Sciences GmbH trials in Czechia

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis Active, not recruiting

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting

Other trials for the same condition

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07286006 on ClinicalTrials.gov ↗ ← All trials in Czechia